Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs
Open Access
- 8 December 2019
- journal article
- editorial
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 25 (3) , e405-e411
Abstract
A number of important drugs used to treat cancer—many of which serve as the backbone of modern chemotherapy regimens—have outdated prescribing information in their drug labeling. The Food and Drug Administration is undertaking a pilot project to develop a process and criteria for updating prescribing information for longstanding oncology drugs, based on the breadth of knowledge the cancer community has accumulated with the use of these drugs over time. This article highlights a number of considerations for labeling updates, including selecting priorities for updating; data sources and evidentiary criteria; as well as the risks, challenges, and opportunities for iterative review to ensure prescribing information for oncology drugs remains relevant to current clinical practice.Keywords
This publication has 8 references indexed in Scilit:
- An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung CancerJCO Clinical Cancer Informatics, 2019
- Cancer During Pregnancy: The Oncologist OverviewWorld Journal of Oncology, 2019
- Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical PracticeTherapeutic Innovation & Regulatory Science, 2018
- Harnessing the Power of Real‐World Evidence (RWE): A Checklist to Ensure Regulatory‐Grade Data QualityClinical Pharmacology & Therapeutics, 2017
- Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research StatementJournal of Clinical Oncology, 2017
- A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group ProgramJNCI: Journal of the National Cancer Institute, 2010
- A National Cancer Clinical Trials System for the 21st Century2010
- Using observational data from registries to compare treatments: The fallacy of omnimetricsStatistics in Medicine, 1984